Establishing clinical guidelines for the management of acute hypersensitivity reactions secondary to the administration of chemotherapy/biologic therapy.
A performance improvement initiative was undertaken to establish treatment guidelines for the management of infusion-related hypersensitivity reactions (iHSRs) secondary to the administration of chemotherapy/biologic therapy and to develop an efficient process to ensure application of these standards in the care of patients at increased risk of experiencing iHSRs. The project yielded a standardized approach that ensures the application of an evidence-based standard of care in managing these reactions. In addition, the effort resulted in improvements in the reporting of this type of adverse drug reaction (ADR) to the institutional ADR reporting program.
Timoney
John P
JP
Division of Pharmacy Services, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Eagan
Mary M
MM
Sklarin
Nancy T
NT
D016907:Adverse Drug Reaction Reporting Systems; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001691:Biological Therapy / Q000009:adverse effects*; D002173:Cancer Care Facilities; D004342:Drug Hypersensitivity / Q000209:etiology / Q000628:therapy; D019317:Evidence-Based Medicine; D006801:Humans; D006967:Hypersensitivity / Q000209:etiology* / Q000628:therapy*; D007262:Infusions, Intravenous / Q000009:adverse effects; D009369:Neoplasms / Q000188:drug therapy*; D009519:New York City; D017410:Practice Guidelines as Topic
D000970:Antineoplastic Agents